BioSpace News Archive

This Hanukkah Pack will be Available Starting November 26, 2020 and will be Strictly Limited to 613 Units Anticipated Price per Unit: $61.30 USD

SIRIO – a leading nutraceutical contract development and manufacturing organisation (CDMO) – has completed a new ‘smart factory’ at its Ma’anshan site, with Internet of Things (IoT) enabled automated processes and monitoring, intelligent distribution robotics and Artificial intelligence (AI).

ams keynote at Fierce Technology event demonstrates innovations in spectral sensing technology which improves rapid access and accuracy in the COVID-19 battle

Gravity Diagnostics is a diagnostic laboratory licensed in all 50 states that responded to the call to test for COVID-19 in early March of 2020, and what an incredible journey it has been so far

A new biotech product from Merion Inc. can help to increase metabolism, repair DNA and support anti-aging.

Launching today is the Alzheimer’s Disease Data Initiative (ADDI) and its Alzheimer’s disease (AD) Workbench, a cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.65 per share of the company’s common stock for the first quarter of 2021. Payment will be made on Jan. 8, 2021 to shareholders of record at the close of business on Dec. 15, 2020. About Merck For more than 125 years, Merck, known as MSD outside of the Unite

Omni-channel virtual care solution will quickly connect clinical staff, members and clients to clinical information and personalized care plans to help streamline care and help improve patient outcomes

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the closing of its public offering of 2,990,000 shares of common stock

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, Chief Medical Officer (“CMO”) of the Company, has tendered his resignation in order to explore opportunities outside of Caladrius.